- The European Commission approved a 7.2 mg dose of Wegovy\u00ae for obesity.
- The approval is based on a positive opinion from the CHMP on 12 December 2025.
- In a study with 1,407 people, the higher dose led to 21% average weight loss.
- Common side effects include nausea, diarrhea, vomiting, and dysaesthesia.
EU Approval
The European Commission has approved a 7.2 mg maintenance dose of Wegovy® (semaglutide) for adults with obesity. This decision allows doctors in all 27 EU countries to prescribe this higher dose for patients needing additional weight loss support.
Study Results
A clinical study involving 1,407 participants over 1½ years showed that those on the 7.2 mg dose lost an average of 21% of their body weight. The study also highlighted that about one-third of participants lost 25% or more of their body weight.
Dosage and Administration
The 7.2 mg dose is administered as three 2.4 mg injections in one sitting, once a week. Novo Nordisk is seeking approval for a single-dose 7.2 mg pen in the EU, which could be available this year. The drug is already approved in the UK, with applications pending in the US and other countries.
Side Effects
Common side effects reported include nausea, diarrhea, vomiting, and dysaesthesia, which were generally mild to moderate and transient. The majority of weight loss was from fat mass, with muscle function preserved.
